ED
AVIR icon

Exane Derivatives’s Atea Pharmaceuticals AVIR Stock Holding History

Exane Derivatives’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$554 Hold
78
– – ﹤0.01% 560
2022
Q1 		$563 Hold
78
– – ﹤0.01% 848
2021
Q4 		$697 Sell
78
-4,688
-98% -$73.1K ﹤0.01% 738
2021
Q3 		$167K Buy
4,766
+576
+14% +$16K 0.04% 431
2021
Q2 		$93.2K Buy
+4,190
New +$126K 0.02% 546

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Exane Derivatives's AVIR Position: Q2 2022 in Review

Exane Derivatives held its Atea Pharmaceuticals (AVIR) position steady in Q2 2022 at 78 shares worth $554. The position accounts for ﹤0.01% of the portfolio, ranked #560.

Exane Derivatives first reported a position in AVIR in Q2 2021 and has held it in 5 quarters since. The position peaked at $167K in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • Exane Derivatives held 78 shares of Atea Pharmaceuticals worth $554 as of Q2 2022.
  • Exane Derivatives left its Atea Pharmaceuticals share count unchanged in Q2 2022.
  • Atea Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #560 holding.
  • Exane Derivatives first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
  • Exane Derivatives's Atea Pharmaceuticals position peaked at $167K in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.